[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study
Crossref DOI link: https://doi.org/10.1186/1750-1172-10-S1-P38
Published Online: 2015-11-02
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dupont, Anne-Claire
Guilloteau, Denis
Ben-Azzouna, Rana
Bidault, Rudy
Algalarrondo, Vincent
Slama, Michel
Arlicot, Nicolas
Le Guludec, Dominique
Text and Data Mining valid from 2015-11-02
Version of Record valid from 2015-11-02
Article History
First Online: 2 November 2015